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Viruses are excellent vehicles for gene therapy due to their natural ability to infect and
deliver the cargo to specific tissues with high efficiency. Although such vectors are usually
“gutted” and are replication defective, they are subjected to clearance by the host cells
by immune recognition and destruction. Unfolded protein response (UPR) is a naturally
evolved cyto-protective signaling pathway which is triggered due to endoplasmic reticulum
(ER) stress caused by accumulation of unfolded/misfolded proteins in its lumen. The UPR
signaling consists of three signaling pathways, namely PKR-like ER kinase, activating
transcription factor 6, and inositol-requiring protein-1. Once activated, UPR triggers the
production of ER molecular chaperones and stress response proteins to help reduce
the protein load within the ER. This occurs by degradation of the misfolded proteins
and ensues in the arrest of protein translation machinery. If the burden of protein load
in ER is beyond its processing capacity, UPR can activate pro-apoptotic pathways or
autophagy leading to cell death. Viruses are naturally evolved in hijacking the host cellular
translation machinery to generate a large amount of proteins. This phenomenon disrupts
ER homeostasis and leads to ER stress. Alternatively, in the case of gutted vectors used in
gene therapy, the excess load of recombinant vectors administered and encountered by
the cell can trigger UPR. Thus, in the context of gene therapy, UPR becomes a major
roadblock that can potentially trigger inflammatory responses against the vectors and
reduce the efficiency of gene transfer.
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INTRODUCTION
One of the important functions of cellular metabolism is pro-
tein folding. Endoplasmic reticulum (ER) is the site where all
the proteins (secreted, membrane bound, and organelle tar-
geted proteins) are typically processed and folded in eukaryotes
(Kaufman et al., 2002; Naidoo, 2009). This accumulates a very
high concentration of proteins in the ER which can lead to co-
aggregation between proteins and/or polypeptides (Stevens and
Argon, 1999). Therefore, the lumen of the ER needs a unique
environment that promotes processing of proteins but prevents
their aggregation (Anelli and Sitia, 2008; Kim et al., 2008; Hetz
et al., 2011; Hetz, 2012). Sometimes, due to a high demand
in protein synthesis due to various physiological reasons, the
processing capacity of the ER can be challenged (Zhang and
Kaufman, 2006; Marcinak and Ron, 2010; Hetz et al., 2011).
This results in an imbalance in the ER environment, which is
referred to as ER stress (Liu and Howell, 2010; Marcinak and
Ron, 2010; Hetz et al., 2011; Iwata and Koizumi, 2012). Altered
protein folding leading to ER stress can be induced by various
factors such as glucose deprivation, aberrant calcium regula-
tion, viral infection and hypoxia. Normally, cells ensure that
proteins are correctly folded using a combination of molecular
chaperones namely, the foldases and lectins (Naidoo, 2009). If
unfolded or misfolded proteins continue to accumulate, eukary-
otes induce the UPR. The basic goal of UPR is to recover the
(lost) homeostasis (adaptation), reduce stress within the ER com-
partment and prevent any cytotoxic effect that might be caused
by misfolded proteins via adaptive mechanisms as well as by
blocking mRNA translation (Xu et al., 2005; Kim et al., 2008; Ye
et al., 2011). During adaptation, the UPR tries to correct folding
homeostasis via induction of chaperones that promote protein
folding (Meusser et al., 2005; Kim et al., 2008). However, when
proper folding cannot be restored, incorrectly folded proteins are
targeted to ER Associated Degradation (ERAD) pathways for pro-
cessing (Kaufman et al., 2002). UPR is also known to trigger
several molecules of the innate immunity pathway, most notably
mitogen- activated protein kinases, p38 and nuclear factor-κB
(NF-κB) which collectively trigger the UPR induced alarm signal
(Ron and Walter, 2007; Kim et al., 2008; Tabas and Ron, 2011)
to remove translational block and down-regulate the expression
and activity of pro-survival factors such as the B-cell lymphoma
2 (Bcl2) protein. However, if the function of the ER cannot be
re-established, UPR eliminates the damaged cells by apoptosis or
autophagy (Bernales et al., 2006; Kamimoto et al., 2006; Yorimitsu
et al., 2006; Hoyer-Hansen et al., 2007; Kouroku et al., 2007).
Apart from such a response against de novo synthesized pro-
teins in a cell, the massive accumulation of exogenous proteins
intra-cellularly as in the case of viral infection is also known to
contribute to ER stress responsive pathways (Zhang and Wang,
2012).
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For a virus to successfully infect mammalian cells, it has
to undergo several aspects in its life-cycle-their attachment
to cell surface receptors, endocytosis, intracellular trafficking,
polypeptide synthesis and genome replication (Balakrishnan and
Jayandharan, 2014). Viruses are naturally evolved to utilize host
cell machinery to successfully complete their life cycle and dur-
ing this process they produce several viral proteins within host
cells. As a natural response to these foreign proteins, the cell
in turn can activate the UPR and interferon response. Thus, a
potential mechanism that can limit viral replication is the UPR.
It is not surprising that viruses have also evolved mechanisms
to manipulate UPR pathways to facilitate their infection (Zhang
and Wang, 2012). This generally involves regulation of stress
response proteins and several molecular chaperones to modulate
UPR and increase ER folding capacity or by induction of transla-
tional attenuation to repress the UPR pathways (Zhang andWang,
2012). Several viruses like adenovirus (Ad), adeno-associated
virus (AAV), dengue virus, cytomegalovirus, respiratory syncytial
virus, simian virus-5, Tula virus, rota virus African swine fever
virus, herpes simplex virus type 1 (HSV-1), hepatitis C virus,
corona virus, influenza virus amongst others have been shown to
regulate host cell UPR machinery to promote their infection and
persistence in the host (Bitko and Barik, 2001; Netherton et al.,
2004; Isler et al., 2005; Paradkar et al., 2011; Pena and Harris,
2011; Zhang and Wang, 2012). For example, rotavirus interrupts
the inositol requiring protein-1 (IRE1) and activating transcrip-
tion factor 6 (ATF6) UPR pathways by translational inhibition
through its non-structural protein NSP3 (Trujillo-Alonso et al.,
2011). Hepatitis C virus (HCV) has been shown to suppress the
IRE1-XBP1 pathway to promote its expression and persistence in
the liver (Tardif et al., 2004). Likewise cytomegalovirus uses the
viral protein M50 to downregulate IRE1 leading to suppression of
UPR (Stahl et al., 2013). This article reviews the tug of war that is
initiated by the cell through its UPR signaling against viruses used
in gene therapy and dissects how this information can be helpful
to improve gene delivery strategies.
UPR PATHWAYS
Three branches of the UPR have been characterized, which are
mediated by ER-located transmembrane proteins: IRE1, pro-
tein kinase RNA-like ER kinase (PERK) and ATF6. The binding
immunoglobulin protein (BiP) is themaster regulator of the UPR.
All the three arms of UPR are held in an inactive state by the bind-
ing of the BiP to their N-terminal region of IRE1, PERK and ATF6
proteins. When the cell encounters stress, BiP is released due to
competitive binding of the misfolded proteins and thus leading to
activation of UPR signaling (Figure 1) (Xu et al., 2005).
IRE1 PATHWAY
IRE1, the most evolutionarily conserved branch of UPR (Cox
et al., 1993) initiates both the pro-survival and pro-apoptotic
components in the presence of misfolded proteins. In mammals
two isoforms of IRE1 have been identified, IRE1α and IRE1β;
IRE1α is expressed in a variety of tissues (Tirasophon et al.,
1998), whereas IRE1β is primarily found in the intestine and
lung (Bertolotti et al., 2001; Martino et al., 2013). Mechanistically,
when there is an increase in unfolded or misfolded protein load,
the BiP molecule interacts with the N-terminus of IRE1, located
in the ER lumen. This sensing leads to dimerization of IRE-1 and
activates two distinct signaling arms of the IRE-1 pathway. The
early signaling occurs through the cleavage of a 26-nucleotide
intron from the XBP1-mRNA (Shen et al., 2001; Yoshida et al.,
2001; Lee et al., 2002; Malhotra and Kaufman, 2007) generat-
ing a 41 kDa frameshift variant (sXBP1). sXBP1 acts as a potent
transcription factor that regulates the expression of several pro-
tein degradation related genes (Rao and Bredesen, 2004;Malhotra
and Kaufman, 2007). The late signaling sensor of IRE1 is initiated
when the cytosolic IRE1α dimers interact with molecules like the
tumor necrosis factor receptor-associated factor 2 (TRAF2) which
activates the signal-regulating kinase (ASK1) and further activa-
tion of cJUN NH2-terminal kinase (JNK) and p38MAPK (Urano
et al., 2000). These proteins in turn trigger a proapoptotic sig-
nal through pro-apoptotic molecules such as Bim and caspase-3
leading to cell death.
PERK PATHWAY
PERK is an ER-localized type I transmembrane protein contain-
ing a catalytic kinase domain homologous to other kinases of
the eukaryotic translation initiation factor 2 (eIF2) such as gen-
eral control non-depressible-2 (GCN2), heme-regulated inhibitor
(HRI) and protein kinase R (PKR) (Harding et al., 1999). The
luminal stress sensor domain of PERK is structurally and func-
tionally homologous with the luminal domain of IRE1α, impli-
cating very similar stress-sensing mechanisms between PERK and
IRE1α (Bertolotti et al., 2000). The PERK branch of UPR trans-
duces both the pro-survival as well as pro-apoptotic signals fol-
lowing the accumulation of unfolded or misfolded proteins in the
ER.However, its main function is tomodulate translation. During
initial stages of ER stress, PERK oligomerizes in the ER mem-
brane and induces autophosphorylation (He, 2006). Activated
PERK phosphorylates eIF2α at S51 (Harding et al., 1999; Raven
et al., 2008) leading to global attenuation of translational machin-
ery, thus reducing the trafficking of newly synthesized proteins
into the already stressed ER compartment. The accumulated pro-
tein load is then cleared off from the ER by ERAD pathway
with simultaneous expression of pro-survival genes like activat-
ing transcription factor 4 (ATF4) (Harding et al., 2003). ATF4 is
not affected by the global eIF2α translational block because of the
presence of internal ribosome entry site (IRES) sequences in the
5′ untranslated regions (Schroder and Kaufman, 2005). However
ATF4 can drive the cell toward apoptosis by inducing expres-
sion of factors like C/EBP homologous protein (CHOP) and
growth arrest and DNA damage-inducible protein 34 (GADD34)
(Zinszner et al., 1998; Novoa et al., 2003).
ATF6 PATHWAY
ATF6 is a type II ER transmembrane protein belonging to the
bZIP family of transcription factors. The ER luminal domain acts
as the sensor for ER stress due to the protein overload while the
cytoplasmic domain acts as a transcription factor (49). ATF6 has
two homologs- ATF6α (Hai et al., 1989; Haze et al., 1999) and
ATF6β (Min et al., 1995; Khanna and Campbell, 1996; Haze et al.,
2001) with redundant roles in UPR. Upon dissociation of BiP
from the N-terminus of ATF6 following ER stress, it translocates
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FIGURE 1 | Unfolded protein response signaling. The signaling is
initiated by the activation of the proximal sensors of the unfolded
protein response (UPR) namely, (1) protein kinase R (PKR)-like ER
kinase (PERK), (2) activating transcription factor (ATF) 6 and (3)
inositol-requiring enzyme 1 (IRE1). A protein called immunoglobulin
heavy chain binding protein (BiP) functions as the master regulator. BiP
under normal conditions remains attached to all the three sensors in
the luminal domain of the endoplasmic reticulum (ER). Upon
encountering any stress like accumulation of misfolded/unfolded proteins
or a massive inflow of any exogenous proteins into the ER, the stress
sensors, PERK, IRE1, and ATF6, are activated by the release of BiP
from the sensors leading to any of the three distinct pathways. (1)
When PERK is activated, it dimerises and autophosphorylates leading to
phosphorylation of the eukaryotic translation initiation factor (elF) 2α.
Activated elF2α represses global protein translation of the cell. However
the downstream protein called ATF 4 can escape translational repression
since it has upstream open reading frames leading to its activation. The
activated ATF4 translocates into the nucleus activating a set of target
genes to restore cellular homeostasis (adaptive response). However in
situations when the cellular homeostasis cannot be restored, C/EBP
homologous protein (CHOP) is activated leading to apoptosis. (2) When
IRE1 is activated, it dimerizes and autophosphorylates leading to the
activation of its endoribonuclease activity. This leads to an unusual
splicing of XBP1 (X-box binding protein 1) cleaving 26 nucleotide intron
within. The Spliced XBP1 (sXBP1) protein translocates to nucleus
transcribing chaperones and unfolded protein response elements
(UPREs) to restore cellular homeostasis. In some cases, the IRE1
activates the cellular JNK through phosphorylation. This activated JNK
either leads to apoptosis by activaton of caspase 19 or leads to
autophagy. Alternatively, IRE1 activates IKK by interacting with tumor
necrosis factor receptor-associated factor 2 (TRAF2) which
phosphorylates IκB. This releases nuclear factor (NF)-κB. The activated
NF-κB translocates into the nucleus and transcribes inflammatory genes.
(3) Activation of the third sensor of UPR, ATF6 leads to its
translocation into the Golgi complex. In the golgi complex, ATF6 will be
cleaved by proteases such as site-1 protease (S1P) and S2P. This
cleaved ATF6 fragment further transcribes chaperones and UPRE to
cope with the cellular stress and restore homeostasis (Yoshida et al.,
2001; Lee et al., 2002; Harding et al., 2003; Novoa et al., 2003; Wu
et al., 2007; Yamamoto et al., 2007; Raven et al., 2008).
from the ER to the golgi where it is cleaved by resident proteases
like site 1 protease (S1P) and site protease (S2P) (Hetz et al.,
2011) to release its cytoplasmic DNA binding fragment called
ATF6f. ATF6f increases degradation of unfolded proteins as well
as induces the activity of several ER chaperone proteins like BiP,
protein disulfide isomerase (PDI) and ER degradation-enhancing
alpha-mannosidase-like protein 1 (EDEM1) (Wu et al., 2007;
Yamamoto et al., 2007).
GENE THERAPY
In the last two decades, gene therapy has been immensely popu-
lar to treat various inherited as well as acquired disorders (Kay,
2011; Misra, 2013). Gene therapy involves either replacing a
mutated gene with a healthy copy or introducing a new gene
into the cells to help protect against the disease. Despite signifi-
cant success seen in the treatment of diseases such as lipoprotein
lipase deficiency (Gaudet et al., 2012), haemophilia B (Manno
et al., 2006; Nathwani et al., 2011), Leber’s Congenital Amaurosis
(Simonelli et al., 2010) or severe combined immunodeficiency
(SCID) (Cavazzana-Calvo et al., 2000), the safety and efficacy
of this novel modality of treatment recognizably needs to be
improved. For a clinically relevant gene therapy protocol, the
efficient delivery and optimal expression of the gene of interest
are very important. Since viruses are naturally evolved to effi-
ciently infect and transfer DNA into the host, engineered (gutted)
viruses are the most desirable as gene delivery vehicles. Viral
vectors currently available for gene therapy can roughly be cat-
egorized into integrating and non-integrating vectors. Vectors
based on retroviruses (including lentivirus and foamy virus) have
the ability to integrate their viral genome into the chromosomal
DNA of the host cell, which can theoretically achieve life-long
gene expression. Vectors based on Ad, AAV and HSV-1 repre-
sent the non-integrating vectors (Table 1). These vectors deliver
their genomes into the nucleus of the target cell, where they
continue to remain episomal. Viral vectors derived from retro-
viruses, Ad, AAV and HSV have been employed in the majority of
gene therapy clinical trials (Table 2). Recognizing the activation
and basis of cellular events like UPR in response to a virus
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Table 1 | Characteristics of the common viruses used in gene therapy.
Viral Vector Description Associated
disease
Maximum
transgene
capacity
Host
genome
integration
Transduction of
cells
Advantages Disadvantages
Adenovirus 36 kb dsDNA,
non-enveloped,
icosahedric,
70–90 nm in
diameter
Yes ∼30 kb No Both dividing and
non-dividing
Easy production of
high titres, ability to
infect a wide range
of cell types,
capacity to carry
large transgene
Adverse host
humoral and cellular
immune response,
transient gene
expression
Retroviruses
(retrovirus and
lentivirus)
7–10 kb ssRNA,
enveloped, ∼100 nm
diameter
Yes ∼8 kb Yes Both dividing and
non-dividing
High infection
efficiency, stable
and permanent
gene transfer
Insertional
mutagenesis causing
cancer, high
immunogenicity
Adeno associated
virus (AAV)
4.7 kb ssDNA,
Icosahedric,
non-enveloped,
∼22nm diameter
No ∼4.7 kb No Both dividing and
non-dividing
Low
immunogenicity,
non-infectious
Limited transgene
carrying capacity,
not suitable to target
rapidly dividing cells
Herpesvirus-HSV-1 ∼152 kb dsDNA,
icosahedric
enveloped, ∼125 nm
diameter
Yes ∼150 kb No Only dividing cells Large transgene
carrying capacity,
production of high
titres
Host immune
response, short term
gene expression
used in gene therapy is important to further optimize gene
delivery.
HSV AND UPR
HSV-1 is a large (∼152 kb) fast replicating, enveloped, double
stranded (ds) DNA virus. The mature viral particle consists of
3 components- an external envelope made of about 13 glycopro-
teins which helps the virus to bind and enter the host cell; a second
layer called tegument which contains 20 different structural and
regulatory proteins and finally an icosohedral capsid contain-
ing the genetic material. HSV is an attractive choice as a gene
therapy vector for various reasons, including its broad tropism,
host range and its cellular receptors (Arii et al., 2009; Fan et al.,
2009; Wang et al., 2009b), their ability to infect non-dividing
cells with high efficiency, high production titers for recombinant
particles and a stable/long-term expression of therapeutic genes
especially in neurons (Norgren and Lehman, 1998). Three types
of HSV-1 vectors are currently in use in gene therapy- replication-
defective, replication-competent vectors and amplicons. Deleting
one or more genes involved in the lytic cycle creates a replication-
defective vector. Replication-competent viruses are attenuated for
genes that are not essential for replication in vitro (Hu and Coffin,
2003; Post et al., 2004). The amplicons are derived from engi-
neered plasmids, which contain both the HSV packaging recog-
nition sequence (pac) and the origin of replication (ori). These
amplicons can be efficiently packaged in mammalian cells as con-
catamers with the help of HSV helper elements. Also, amplicons
are non-toxic and can carry very large DNA fragments of upto
152 kb (Epstein, 2009). Both replication defective and replication
competent HSV vectors have been used in gene therapy of sev-
eral neurological disorders (Table 1). Replication defective HSV
vectors have been shown to efficiently transduce both dividing
and non-dividing cells including tumors. Taking advantage of this
property, HSV vector have been engineered to deliver anticancer
transgenes into tumour cells such as melanoma (Krisky et al.,
1998; Niranjan et al., 2003), gliosarcoma (Moriuchi et al., 2002;
Niranjan et al., 2003) or glioblastoma (Niranjan et al., 2000).
One of the major factor that negatively affects HSV mediated
gene delivery is the host immune response directed against it,
including the innate and adaptive responses (Ryan and Federoff,
2009). As a first line of defense, innate immunity is a major rate-
limiting factor in HSV transduction. One of the principal effector
underlying anti-HSV innate defense, is the process of autophagy
that is initiated through the cellular UPR pathway (Lee et al.,
2009).
During replication of HSV, there is a rapid generation of
large amount of viral proteins that may induce UPR and con-
sequently necessitate modulation of the cellular stress response
(Figure 2A). Indeed, a number of HSV-1 proteins have been
shown to block phosphorylation of eIF2α, an important stress
response mechanism of the cell, which leads to the attenuation
of protein synthesis (He et al., 1996; Cassady et al., 1998; Mulvey
et al., 2003, 2006, 2007). Cassady et al. (1998) and Mulvey et al.
(2003) showed that a HSV viral protein, US11 can repress two
kinases (eIF2α, PKR) and PERK upon HSV infection (Figure 2A)
(Cassady et al., 1998; Mulvey et al., 2003). He et al., demon-
strated that a late protein γ134.5 can dephosphorylate eIF2α with
the help of the cellular phosphatase PP1α (He et al., 1996). This
inhibition resulted in a 1000-fold increase in the replication effi-
ciency of HSV1 (Talloczy et al., 2006). It has been shown that
HSV-1 infection does not activate PERK as well as IRE and was
also highly resistant to acute ER stress (Mulvey et al., 2007).
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Table 2 | Viral vectors used in clinical trials (Last date of access—24th March, 2014).
Viral vectors Disease target Clinicaltrials.gov Last update
identifier
Adenovirus Cystic fibrosis NCT00004779 June 23, 2005
Ovarian cancer NCT00964756;
NCT00562003
February 11, 2013;
January 25, 2011
Metastatic breast cancer NCT00307229;
NCT00197522
May 31, 2012;
October 31, 2012
Lung cancer NCT00776295 January 16, 2013
Brain tumor NCT00004080 February 6, 2009
melanoma NCT01397708 March 11, 2014
Bladder cancer NCT00003167 January 22, 2013
Adeno-associated virus (AAV) Retinal disease NCT01482195 November 29, 2011
Pompe disease NCT00976352 December 13, 2013
Late infantile neuronal ceroid lipofuscinosis NCT01161576 November 5, 2013
Leber congenital amaurosis NCT00749957;
NCT00643747;
NCT00999609;
NCT00516477
March 6, 2013;
December 13, 2013;
January 13, 2014;
January 13, 2014
Alpha-1 antitrypsin deficiency NCT01054339;
NCT00377416;
NCT00430768
March 6, 2013;
December 20, 2013;
December 20, 2013
Cystic fibrosis NCT00004533 June 23, 2005
Idiopathic Parkinson’s disease NCT00985517 December 10, 2012
Hemophilia B NCT01687608;
NCT01620801;
NCT00076557;
NCT00515710;
NCT00979238
September 19, 2013;
December 20, 2013;
April 2, 2007;
December 20, 2013;
December 20, 2013
Duchenne muscular dystrophy NCT00428935 February 4, 2013
Lipoprotein lipase deficiency NCT01109498;
NCT00891306
September 29, 2011;
September 28, 2011
Herpes simplex virus vectors Melanoma, liver cancer, pancreatic cancer, lung cancer NCT01935453 August 30, 2013
Refractory non-central nervous system (non-CNS) solid tumors NCT00931931 November 5, 2013
Head and neck cancer or solid tumors NCT01017185 February 18, 2013
Lentivirus Lymphoma NCT00569985 January 6, 2014
Acute myeloid leukaemia NCT00718250 July 16, 2008
ADA-deficient severe combined immunodeficiency (ADA-SCID) NCT01852071 January 14, 2014
X-linked severe combined immunodeficiency (X-SCID) NCT01306019 March 14, 2014
Fanconi anaemia NCT01331018 March 6, 2014
Wiskott—aldrich syndrome NCT01515462 January 18, 2012
AIDS-related non-hodgkin lymphoma NCT01961063 October 30, 2013
Retrovirus Chronic granulomatous disease NCT00778882 January 15, 2014
CNS tumors NCT00005796 October 22, 2009
X-Linked severe combined immunodeficiency (X-SCID) NCT00028236 July 26, 2011
ADA-deficient severe combined immunodeficiency (ADA-SCID) NCT00598481;
NCT00599781;
NCT00794508
December 12, 2013;
January 23, 2008;
February 7, 2013
Leukocyte adherence deficiency NCT00023010 December 14, 2010
Chronic granulomatous disease (CGD) NCT00564759;
NCT00001476
November 27, 2007;
December 14, 2010
Gaucher’s disease NCT00001234 March 3, 2008
Sickle cell anaemia and β-thalassemia NCT00669305 December 20, 2013
Mild hunter synrome NCT00004454 June 23, 2005
HIV infection NCT00001535 February 7, 2008
Gyrate atrophy NCT00001735 March 3, 2008
www.frontiersin.org May 2014 | Volume 5 | Article 250 | 5
Sen et al. UPR against viral vectors
This resistance of PERK toward activation by ER stress in HSV-1
infected cells is attributed to the glycoprotein B (gB) associated
with the luminal region of PERK (Figure 2A). This study also
showed a genetic association between PERK and gB which could
regulate the viral protein load in infected cells (Mulvey et al.,
2007). To further understand how HSV1 modulates cellular UPR,
Burnett et al., reported that HSV-1 can deactivate UPR in the early
stages of infection (Burnett et al., 2012). The study observed early
FIGURE 2 | Continued
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FIGURE 2 | (A) Herpes simplex virus (HSV-1) and UPR. HSV-1 produces
proteins such as glycoprotein B (gB) and US11 that have been shown to
evade the host UPR mechanism (Mulvey et al., 2003, 2007). In particular, the
protein gB specifically binds to the PERK proteins preventing their
phosphorylation. This leads to PERK inactivation and hence the downstream
effector protein elF2α could not get activated leading to ATF4 repression.
Alternatively another viral protein called US11 represses the elF2α
phosphorylation by directly binding to it. The late HSV viral protein γ134.5
also induces dephosphorylation of eIF2α with the help of the cellular
phosphatase PP1α (He et al., 1996). This leads to early repression of ATF4
and CHOP genes downstream. Thus the host UPR response is attenuated
and leads to successful viral transduction. (B) Adenovirus (Ad) and UPR.
Adenoviruses during their late phase of their infection, try to overcome the
cellular stress response by preventing the shutdown of protein translation
through PKR mediated inhibition of elF2α phosphorylation via viral associated
(Continued)
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FIGURE 2 | Continued
RNA molecule I (VAI RNA) as well as double-stranded RNA-activated inhibitor
(DAI) (Huang and Schneider, 1990; Mathews and Shenk, 1991; McKenna
et al., 2006). Other Ad proteins such as E1B and E4 has also been found to
directly bind to the elF2α, thus preventing its phosphorylation and activation
of downstream UPR related genes like ATF4 and CHOP (Spurgeon and
Ornelles, 2009). (C) Adeno associated virus (AAV) and UPR. When the
cellular ER encounters AAV particles, specific stress sensors, PERK and IRE1
gets activated (Balakrishnan et al., 2013). PERK phosphorylation leads to the
activation of the elF2α through phosphorylation. The phosphorylated elF2α
further activates the activating transcription factor 4 (ATF4) the protein of
which translocates into the nucleus transcribing UPR responsive genes
necessary to cope up with the cellular stress. The phosphorylated elF2α also
arrests the translation of cellular proteins to maintain homeostasis. It has
been noted that the AAV particles also activates IRE1 which induces the
unusual splicing of X-box binding protein 1 (XBP1) mRNA downstream. The
XBP1 protein translocates into the nucleus activating a set of UPR responsive
elements. The IRE1 also activates the IKK leading to NF-κB upregulation. The
activated NF-κB further activates the inflammatory genes thus inducing an
inflammatory response (Jayandharan et al., 2011; Balakrishnan et al., 2013).
(D) Murine leukemia virus (MLV) and UPR. MLV based γ-retroviral vectors,
which are the most common used in gene therapy, has been showed to
induce neuropathogenecity in astrocytes (Dimcheff et al., 2003). Later in
NIH3T3 cells it was shown that the murine retroviruses induce the ER stress
related genes such as CHOP/GADD153 which leads to apoptosis (Dimcheff
et al., 2003). On the other hand, the lentiviral proteins such as Tat and Nef
have been shown to activate unfolded protein response elements (UPRE) by
increasing ROS (Tiede et al., 2011; Abbas et al., 2012).
repression (less that 24 h post infection) of ATF4 and CHOP due
to inhibition of phosphorylation of eIF2α. ICP0, an immediate-
early Ad gene product known to have transcription factor capa-
bilities (Yao and Schaffer, 1994), was found to be the primary
factor triggering activation of the UPR enhancers during HSV-
1 replication, thus helping the virus to sense it at an early stage.
Consistent to a previous finding (Mulvey et al., 2003), XBP1(for
the IRE1 signaling pathway) remained inactive in this study
as well.
Ad AND UPR
Ads are non-enveloped DNA viruses whose genome is com-
prised of a linear 36 kb double-stranded DNA. The recombinant
Ad vectors were first used as a gene transfer agent in 1985
(Ballay et al., 1985; Yamada et al., 1985) and since then have
been used as a vehicle for various monogenic diseases (Porteus
et al., 2006). For example, Ad vectors expressing cystic fibro-
sis transmembrane conductance regulator CFTR have been used
in phase I clinical studies to treat cystic fibrosis (Zuckerman
et al., 1999). Muscular dystrophy is another disease where atten-
uated Ad vectors have been used to deliver dystrophin cDNA
into muscle tissue (Clemens et al., 1996; Haecker et al., 1996;
Floyd et al., 1998). Improved Ad vectors have also been used to
deliver human coagulation factors VIII and IX for phenotypic
correction of hemophilia in preclinical animal models (Zhang,
1999). These vectors have been used in the treatment of several
other metabolic and genetic diseases like lysosomal storage dis-
ease, phenylketonuria and glycogen storage disease (Amalfitano
et al., 1999; Nagasaki et al., 1999; Ziegler et al., 1999; Eto and
Ohashi, 2000; Stein et al., 2000; Zingone et al., 2000), neurologi-
cal disorders like Parkinson/Alzheimer’s as well as cardiovascular
diseases like atherosclerosis, cerebral ischemia and in cancer ther-
apy (Donahue et al., 2000; Papadopoulos et al., 2000; Choi and
Yun, 2013).
As is the case of any foreign protein, Ad vectors are also sub-
ject to severe inflammatory response, which lead to their clearance
and achieves only transient gene expression in the target tissue.
One of the major transcription factor that serves as the media-
tor of inflammatory response is NF-κB, which can be activated
by various pathological stimuli like bacterial/viral infection and
the inflammatory cytokines. It has been shown previously that
accumulation of protein load in the ER can activate NF-κB via
the PERK and IRE-1 pathway (Tam et al., 2012). It has been
demonstrated that the Ad E3/19 K protein can activate NF-κB
mediated by Ca2+ release from the ER following a protein over-
load, in vitro. As a result, NF-κB activates inflammatory cytokines
and interferons that constitute the initial anti-viral response of
the cells (Pahl and Baeuerle, 1995). As with most viruses, in the
late phase of productive infection, viral protein synthesis is pro-
moted in Ad-infected cells while simultaneously inhibiting the
cellular protein synthesis. One of the ways Ad does this, is by
inhibition of PKR-mediated eIF2α phosphorylation along with
the activation of a protein kinase called double-stranded RNA-
activated inhibitor (DAI) (Huang and Schneider, 1990). It has also
been shown that the non-coding Ad associated RNA molecule I
(VAI RNA) can suppress PKR activation by directly binding to
it (Mathews and Shenk, 1991; McKenna et al., 2006). VAI RNA
is highly expressed during the late phase of Ad infection when
it is transcribed by a RNA polymerase III (Soderlund et al., 1976;
Thimmappaya et al., 1982; Svensson and Akusjarvi, 1984). It plays
a crucial role in preventing shutdown of cellular translational
apparatus by inhibiting eIF2α phosphorylation and the activation
of PKR, although the precise mechanism remains unclear (Huang
and Schneider, 1990). Spergeon et al., have also shown the role of
Ad E1B 55-Kd and E4 Open Reading Frame 6 Proteins in pro-
moting its infection in the late phase. These Ad proteins were
shown to limit phosphorylation of eIF2α phosphorylation and
PKR activation (Figure 2B). This process requires the functioning
of the Cul5-mediated E3 ubiquitin-protein ligase of the E1B-
55K/E4orf6 complex which is independent of the cytoplasmic
levels of VAI RNA (Spurgeon and Ornelles, 2009).
AAV AND UPR
Naturally occurring AAV is small (∼22 nm), non-enveloped and
contains single-stranded DNA (∼4.7 kb). It belongs to the fam-
ily Parvoviridae, and the genus Dependovirus (Balakrishnan and
Jayandharan, 2014). The genome contains two open reading
frames encoding the genes, rep (responsible for replication) and
cap (encodes capsid specific proteins) flanked by a 145 base pair
long inverted terminal repeat (ITR) sequence. AAV enters the
infective cycle only in presence of other helper virus such as
Ad or HSV (Daya and Berns, 2008). Recombinant AAV is pro-
duced by stuffing the transgene of interest between the flanking
ITRs while the rep and cap genes are supplied in trans along
with helper function genes (Wright, 2009). Currently, AAV is
the choice vector for many inherited and non-inherited diseases
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because of its non-pathogenic nature. Another major advantage
of using AAV as a gene therapy vector is its low immune pro-
file when compared to Ad vectors (Asokan et al., 2012). So far
12 AAV serotypes (AAV1-12) has been used as gene therapy vec-
tors although several other serovars are known to exist. AAV is
naturally hepatotrophic that makes them an attractive choice for
liver targeted gene therapy for the treatment of diseases such
as hemophilia and alpha1 antitrypsin deficiency (Flotte et al.,
2011; Nathwani et al., 2011). However several other alternate
serotypes like AAV1, AAV5, AAV9, and rh10 have shown signif-
icant promise in targeting tissues like the muscle and the central
nervous system (Zincarelli et al., 2008; Tang et al., 2010; Rafi et al.,
2012; Gray et al., 2013). Unfortunately, the vector dose-dependent
immune response and the presence of pre-existing neutralizing
antibody against AAV capsids can limit persistent gene expres-
sion in humans (Manno et al., 2006; Boutin et al., 2010). It is
known that AAV, after receptor mediated endcocytosis, undergoes
trafficking through the endocytic compartments followed by ret-
rograde transport to the Golgi or the ER (Ding et al., 2005). It has
been shown earlier that intracellular trafficking of AAV is nega-
tively regulated by components of the ER stress response (Duan
et al., 1999; Douar et al., 2001; Ding et al., 2003). For example
AAV mediated human factor (F).VIII gene expression improved
by ∼300–600% upon inhibiting the proteasomal machinery by
using pharmacological agents like bortezomib in preclinical ani-
mal models of haemophilia (Monahan et al., 2010). Thus, it is
quite logical to note that during intracellular trafficking, ER stress
could play an inhibitory role in AAV life cycle. Indeed, we have
recently shown the role of UPR in AAV infection (Balakrishnan
et al., 2013). In this study self-complementary (sc) AAV2 was
shown to activate the PERK and IRE-1 pathway in HeLa cells
with peak activation 12 h post-infection. ATF6 however was not
induced by scAAV2. Interestingly, single-stranded (ss) AAV2 did
not induce UPR effectors as dominantly as scAAV2 although it
modestly activated PERK and IRE-1. The activation of PERK
and IRE-1 was further confirmed by an increased expression of
downstream signaling molecules like CHOP and spliced XBP-1,
respectively. Inhibiting PERK and or IRE-1 expression in in vitro
(using shRNA against PERK/IRE-1) and in vivo (metformin, i.p)
led to a modest increase in gene expression from scAAV2 vec-
tors (Figure 2C). Interestingly, this study also found that alternate
AAV serotype vectors like AAV1 and AAV6 can activate distinct
arms of UPR. For example, scAAV6 had a comparable effect on
PERK activation but not on IRE-1 as scAAV2 vectors. Another
observation was the ablation of innate immune response mark-
ers following UPR inhibition in vivo. This clearly points to the
link between UPR activation and clearing of the vectors through
innate immune response. It has been shown previously that AAV
can activate the classical NF-κB pathway during the acute phase
of infection and trigger downstream inflammatory markers like
TNF-α, IL1a, IL6, and leading to the activation of the adaptive
immune response (Jayandharan et al., 2011). It is also known that
UPR caused by protein overload can activate cellular NF-κB in
the early phase while it is inhibitory in the late phase (Kitamura,
2011) (Figure 2C). Thus, the UPR pathway becomes an impor-
tant target to reduce inflammatory response in the early stages
of AAV infection and to further enhance the persistence and
gene expression from AAV vectors. Interestingly, the efficiency of
AAV transduction is also known to improve under general cel-
lular stress as shown earlier in cellular models of cystic fibrosis
(Johnson et al., 2011).
RETRO-/LENTI-VIRUS AND UPR
Historically, vectors based on retrovirus which were the first viral
vector system described in the early 1980s (Douar et al., 2001)
have been the most preferred in clinical gene therapy due to their
properties of efficient host DNA integration and persistent gene
expression. However, in the clinical trial involving infants with
X-SCID, 4 out of 9 patients developed leukemia due to random
retroviral integration, this remains a major concern with retro-
virus based gene therapy (Cavazzana-Calvo et al., 2000; Kohn
et al., 2003). Lentivirus, that belongs to the retroviridae family
is also known to facilitate stable integration of the viral genome
into the host chromosome. Over the past decade, more than 30
patients with different immunodeficiency disorders have been
treated successfully using murine leukemia virus (MLV)-based
γ-retroviral vectors to transfer therapeutic genes to autologous
hematopoietic cells (Aiuti et al., 2002; Aiuti and Roncarolo, 2009).
However, random integration of the lentiviral vectors is also
known (Wang et al., 2009a). Although not many studies have
been conducted to understand if and how retro- or lenti-viruses
combat UPR, there is some evidence that retroviruses can induce
ER stress. In Shikova et al. (1993) first showed in cultured astro-
cytes that neuropathogenicity of MLV viruses may be related to
protein misfolding in the ER (Shikova et al., 1993). In Dimcheff
et al. (2003) demonstrated that a mouse retrovirus FrCasE is
able to induce ER stress related genes like CHOP/GADD153
and Bip in vitro in NIH3T3 cells as well as in vivo which cor-
related with the induction of spongiform neurodegeneration
(Figure 2D) (Dimcheff et al., 2003). Similarly, mink cell focus-
forming murine leukemia virus (MCF13 MLV) has been shown
to trigger UPR in mink cells following large accumulation of
the viral protein MLV gPr80env via upregulation of CHOP pro-
teins (Nanua and Yoshimura, 2004). A Lentivirus-HIV-1 protein
called the trans-activator of transcription (Tat) has been reported
to induce UPR by increasing reactive oxygen species (ROS) in
primary rat striatal neurons indicating that ER stress response
could be a critical parameter to control during HIV infection
(Figure 2D) (Tiede et al., 2011). Another HIV viral protein called
Nef, known to increase infectivity and replication in lymphocytes
and macrophages has been shown to directly interact with the
eukaryotic elongation factor (eEF)-1α resulting in its cytoplas-
mic relocalization and the inhibition of stress-induced apoptosis.
Conversely, the nuclear re-localization of the Nef/eEF1α complex
can decrease mitochondrial cytochrome c release, thereby inhibit-
ing the caspase activation. This mechanism demonstrates how
the lentivirus (HIV) can prevent cell death under conditions of
stress condition yet is able to create an environment favoring opti-
mal viral replication (Abbas et al., 2012) (Figure 2D). Another
unique retrovirus called Foamy viruses (FVs) have also been
extensively studied as a gene therapy vector due to their lack of
pathogenicity, broad tissue tropism and the ability to carry large
(minimum ∼9.2 kb) transgenes (Heneine et al., 2003; Trobridge,
2009). Hematopoietic stem cell (HSC) gene therapy is one area
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where FVs have been extensively evaluated with considerable suc-
cess (Josephson et al., 2004; Bauer et al., 2008). However there
are no published evidence which have studied the interaction
between FVs and cellular UPR. However it is possible that like
other retro-/lenti- viruses, FVs would have developed mechanism
to either counteract or utilize the UPR machinery to enhance its
own replication in the infected cells.
OTHER VIRAL VECTORS AND UPR
In addition to the commonly used viral vectors described above,
attempts have beenmade to utilize other viruses as vectors for cer-
tain disease conditions. For example, Vaccinia viral vectors have
been in use as a potential therapeutic for cancer gene therapy
(Yu et al., 2009; Seubert et al., 2011) mainly because of its effi-
cient infection and gene expression in a wide range of difficult
to transduce tumors (Yu et al., 2004) as well as their inability
to integrate into the chromosome (Shen and Nemunaitis, 2005).
Also, the safety profile of Vaccinia virus as a therapeutic agent
is well understood due to its long and widespread use as a vac-
cine for small pox in humans. Like most viruses, vaccinia virus
also regulates the cellular UPR machinery to facilitate its infec-
tion. For example, a vaccinia viral protein K3L which has ∼28%
sequence identity with eIF-2a is thought to function as a pseudo
substrate for its kinase, thus blocking the PKR activity and leading
to the inhibition of PERK and eIF2αmolecules (Sood et al., 2000).
Following ER stress response, another Vaccinia protein called F1L
can indirectly inhibit the activation of the apoptotic protein Baxby
by interacting with the proapoptotic BH3-only proteins through
Bak and Bax (Taylor et al., 2006).
Varicella zoster virus (VZV), the causative agent of vari-
cella (chickenpox) and zoster (shingles) and a member of the
Herpesviridae family has also been tested as a cancer gene ther-
apy vector (Degreve et al., 1997). VZV has been shown to induce
cellular UPR through ER stress in vitro. It has been shown to acti-
vate both the IRE-1 and the CHOP pathway and ultimately leads
to autophagy (Carpenter et al., 2011). This study also confirmed
that the VZV structural glycoproteins—gE (ORF68), gI (ORF67),
gH (ORF37), and gL (ORF60) were enough to induce UPR during
an active viral infection.
Epstein–Barr virus (EBV) is a member of the Herpesviridae
family that has a natural tropism for B cells. This property of the
virus has been utilized to deliver GM-CSF to human B cells from
B-cell chronic lymphocytic leukemia (B-CLL) patients as a poten-
tial immune therapy (Hellebrand et al., 2006). However, since
EBV is associated with a number of human malignancies, rigor-
ous vector modification and validation is called for prior to its
application as a gene delivery vehicle in humans. The latent mem-
brane protein 1 (LMP1) oncogene of EBV is shown to induce the
phosphorylation of eIF2α by activating all the three arms of UPR,
the PERK, IRE-1, and ATF6 pathways. This activation in turn
up-regulates LMP1, which leads to induction and maintenance
of the proliferating B lymphocytes (Lee and Sugden, 2008). Thus
it seems that the UPR pathway is required for EBV to enter into
its lytic stage toward maintaining its proliferative and infectious
life-cycle (Taylor et al., 2011).
Sendai virus (SeV) is a negative strand RNA virus which uti-
lizes sialic acid residue or a sialoglycoprotein as their receptor
for cell entry (Markwell et al., 1981). The major advantages
of using recombinant SeV as a gene therapy vector is its non-
pathogenicity and the ability to be generated in high titre during
packaging process. Preclinical studies have shown that SeV can
transduce different cell types like vascular tissue (Masaki et al.,
2001), skeletal muscle (Shiotani et al., 2001), airway epithelial
cells (Yonemitsu et al., 2000) and synovial cells (Yamashita et al.,
2002), quite efficiently. Further, it has been shown that SeV vec-
tor can efficiently transfer its cargo to CD34+ cell and CD34+
cell subpopulations derived from human cord blood (Jin et al.,
2003). In addition, SeV was also able to get stable gene expres-
sion in myeloid, erythroid or mixed progenitor cells (Jin et al.,
2003). However, since SeV induces cytopathic effects in infected
cells, toxicity concerns remain. SeV has been shown to upregu-
late CXCL2 protein following ER stress, which can lead to cell
death via activation of caspase-8 and caspase-3 mediated apopto-
sis (Bitzer et al., 1999; Versteeg et al., 2007). It is also thought that
this virus can activate eIF2α kinases like PERK and PKR to induce
IFN regulatory factor (IRF) 7, a major player in host antiviral
innate response. ATF4, another key regulator of cellular response
to viral infection can be upregulated via phosphorylation of eIF2α
and the activation of IRF7 ultimately helping in cellular recovery
(Liang et al., 2011).
Alphavirus vectors based on Sindbisvirus (SINV) and Semliki
Forest virus (SFV) is another group of virus that has been eval-
uated as a gene therapy vector because of advantages like broad
host range, efficient replication in the cytoplasm and the capacity
to produce high levels of recombinant proteins. Several preclini-
cal studies have been conducted so far to evaluate the efficiency
of alphaviruses as a gene transfer vehicle. For example, SFV was
shown to transduce cardiovascular cells as well as human tumor
cells to deliver IL-12 (Roks et al., 1997; Zhang et al., 1997).
Alphaviral vectors have also been looked upon as a potential
delivery vehicle for DNA-based vaccines (Berglund et al., 1997,
1998). More recently, SFV was used for gene transfer into the cen-
tral nervous system but was also toxic (Graham et al., 2006). In
mammalian cells, SFV envelope glycoproteins activate the UPR
response through induction of CHOP proteins and its consequent
upregulation of caspase-3, caspase-8, and caspase-9 apoptotic
enzymes (Barry et al., 2010). SFV has also been shown to have
delayed RNA synthesis in the presence of Brefeldin A, a potent
UPR inducer (Molina et al., 2007). Another report suggests that
PERK can suppress SFV viral replication at an early stage by elic-
iting strong interferon response in the mouse brain (Barry et al.,
2009). One study revealed that the alpha virus SINV could acti-
vate PERK and IRE-1 but not the ATF6 within 48 h of infection
in vitro. In this study, SINV uncontrollably activated the UPR by
phosphorylation of eIF2α and leading to apoptosis (Rathore et al.,
2013). Moreover SINV has been shown to promote autophagy in
neuronal cells both in in vitro and in vivo probably via activation
of the UPR pathways, thus limiting the spread of viral infection
(Orvedahl et al., 2010; Shi and Luo, 2012).
STRATEGIES TO INHIBIT UPR AGAINST VIRUSES USED IN
GENE TRANSFER
One of the ways to inhibit UPR is through small molecule
inhibitors, which can repress the cellular proteasomal machinery.
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For example, the use of pharmacological agents that inhibit
proteasomes like metformin, MG-132, and ricin has been pre-
viously shown to reduce cellular UPR (Lee et al., 2003; Parikh
et al., 2008; Amanso et al., 2011; Theriault et al., 2011). We
have previously shown that scAAV2 upregulates PERK and IRE-
1α genes in murine liver, ∼24 h post vector administration
(Balakrishnan et al., 2013). This effect was reversed when animals
were pretreated with metformin (250mg/kg). More importantly,
it was also found that attenuation of the UPR response against
AAV also inhibited the expression of various inflammatory
cytokines and chemokines like Chemokine (C-Cmotif) ligand 12
(Ccl12), Chemokine (C-C motif) ligand 11 (Ccl11), Chemokine
(C-C motif) ligand 22 (Ccl22), Chemokine C-X-C motif lig-
and 13 (CXCL13), Chemokine (C-C motif) ligand 24 (Ccl24),
Chemokine C-C motif receptor 2 (Ccr2) and chemokine C-X-C
motif ligand 15 (CXCL15) (Balakrishnan et al., 2013). Thus,
inhibiting the UPR by proteasomal repressors could potentially
reduce innate immune response against AAV leading to higher
and probably persistent gene expression. However, it is a known
fact that systemic administration of proteasomal inhibitors can
have adverse effects (Rajkumar et al., 2005). It is however con-
ceivable that transient inhibition of UPR pathways prior to gene
transfer and during the initial period of viral infection might lead
to improved gene transfer efficiency. Another way to repress UPR
could be by the use of silencing (si) RNAs against specific com-
ponents of the UPR pathway. Our study had previously shown a
modest increase in transgene expression from AAV vectors when
the PERK and IRE-1α pathways were inhibited by specific siRNA
in vitro (Balakrishnan et al., 2013). shRNAs against UPR com-
ponents can also be potentially tested in vivo. Such shRNAs can
be delivered under inducible promoters to avoid adverse effects
caused by long term suppression of UPR machinery.
To avoid immune mediated clearance of viral vectors during
gene therapy, ideally the vector dose should be kept to the mini-
mum. This would allow the vectors to not only to escape the host
immune surveillance before entering the target cells, but may also
reduce cellular stress. To this end, vector bioengineering becomes
a very important tool by which novel, optimized vectors can be
created as described earlier with AAV (Markusic et al., 2010; Qiao
et al., 2010; Gabriel et al., 2013; Sen et al., 2013a,b) to achieve
efficient gene transfer at lower vector doses.
CONCLUSIONS
In higher eukaryotes, UPR is a beneficial process that protects the
cell from undue stress. Cellular UPR strives to reduce the bur-
den on the ER by enhancing its capacity with the help of several
stress response chaperones. If this process becomes futile, UPR
can induce apoptosis of the host cell. Most viruses reprogram
the cellular translational machinery to facilitate the generation of
their proteins, but this process can also trigger the UPR pathways,
which consequently may lead to cell death. For successful gene
therapy, the survival of the transduced cells is very important to
achieve sustained gene expression. In this scenario, transient inhi-
bition of UPR prior to gene transfer, by strategies discussed above,
provides an attractive alternative to improving the safety and
efficiency of viral gene therapy. However, further detailed under-
standing of the sub-cellular processes that activate UPR against
such viral vectors is also necessary to tailor specific strategies and
to shift the balance in favor of virus persistence in the host without
compromising either of their survival.
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